Report in Brief
A review of interferon-free regimens for the treatment of patients with genotype 1 chronic HCV infection will help to inform treatment decisions for these patients.
SVR rates were lower for patients who only received sofosbuvir plus ribavirin. *
The incidence of serious side effects was low. Cost-effectiveness in a Canadian context was uncertain.
*These regimens are currently not approved in Canada.
- What is the evidence for the clinical effectiveness and safety of boceprevir, simeprevir, sofosbuvir, and telaprevir interferon-free regimens?
- What is the cost-effectiveness of boceprevir, simeprevir, sofosbuvir, and telaprevir interferon-free regimens?
The available evidence from the clinical trials indicates that sustained virological response (SVR) was achieved by more than 90% of patients who received sofosbuvir (SOF) and ledipasvir (LDV) with or without ribavirin (RBV) for 8, 12 or 24 weeks; SOF and daclatasvir (DCV) with or without RBV for 12 or 24 weeks; SOF and GS-9669 plus RBV for 12 weeks in treatment naïve and treatment experienced patients. Lower rates of SVR were reported in those who only received SOF plus RBV. Serious AEs and discontinuation due to AEs were low and anemia, rash and depression were low in patients who did not receive RBV. LDV, DCV and GS-9669 have not yet received Health Canada Notice of Compliance (NOC). Two economic evaluations conducted outside of Canada demonstrated that SOF plus simeprivir (SIM) is more cost-effective than SOF plus RBV. However, cost-effectiveness of SOF plus SIM in a Canadian population is uncertain.
hepatitis c, liver, hepatitis, IFN free, Incivek, Victrelis, Sovaldi, Galexos, genotype 1, genotype one